Evidence map›Paper›PMID 36189356›Full record

ReviewFrontiers in cellular and infection microbiology2022

SARS-CoV-2 induced hepatic injuries and liver complications.

Umar Saeed, Zahra Zahid Piracha, Sara Rizwan Uppal, Yasir Waheed, Rizwan Uppal

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Umar SaeedDepartment of Research and Development, Islamabad Diagnostic Center (IDC), Islamabad, Pakistan.
Zahra Zahid PirachaDepartment of Research and Development, Islamabad Diagnostic Center (IDC), Islamabad, Pakistan.
Sara Rizwan UppalDepartment of Research and Development, Islamabad Diagnostic Center (IDC), Islamabad, Pakistan.
Yasir WaheedDepartment of ORIC, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad, Pakistan.
Rizwan UppalDepartment of Research and Development, Islamabad Diagnostic Center (IDC), Islamabad, Pakistan.
Shaheed Zulfiqar Ali Bhutto Institute of Science and Technology · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is resilient, highly pathogenic, and rapidly transmissible. COVID-19 patients have been reported to have underlying chronic liver abnormalities linked to hepatic dysfunction. Discussion: Viral RNAs are detectable in fecal samples by RT-PCR even after negative respiratory samples, which suggests that SARS-CoV-2 can affect the gastrointestinal tract and the liver. The case fatality rates are higher among the elderly and those with underlying comorbidities such as hypertension, diabetes, liver abnormality, and heart disease. There is insufficient research on signaling pathways. Identification of molecular mechanisms involved in SARS-CoV-2-induced damages to hepatocytes is challenging. Herein, we demonstrated the multifactorial effects of SARS-CoV-2 on liver injury such as psychological stress, immunopathogenesis, systemic inflammation, ischemia and hypoxia, drug toxicity, antibody-dependent enhancement (ADE) of infection, and several others which can significantly damage the liver. Conclusion: During the COVID-19 pandemic, it is necessary for clinicians across the globe to pay attention to SARS-CoV-2-mediated liver injury to manage the rising burden of hepatocellular carcinoma. To face the challenges during the resumption of clinical services for patients with pre-existing liver abnormalities and HCC, the impact of SARS-CoV-2 on hepatocytes should be investigated both

Indexed as

Carcinoma, HepatocellularCOVID-19Gastrointestinal DiseasesLiver NeoplasmsAgedHumansLiverPandemicsSARS-CoV-2COVID-19hepatic dysfunctionhepatocellular carcinomaimmunopathogenesisliver injurymechanism of liver damageSARS-CoV-2

Identifiers

PMID36189356
PMCPMC9523111
OpenAlexW4296046282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.